Results of the post-market Registry to Evaluate the Heart Ware Left Ventricular Assist System (ReVOLVE)

JOURNAL OF HEART AND LUNG TRANSPLANTATION

卷:33

Article

Strueber, Martin^1,2  Larbalestier, Robert³  Jansz, Paul.⁴  Zimpfer, Daniel⁵  Fiane, Arnt E.⁶  Tsui, Steven⁷  Simon, Andre⁸  Schmitto, Jan D.¹  Khaghani, Asghar⁸  Wieselthaler, George M.⁵  Najarian, Kevin⁹  Schueler, Stephan¹⁰ 

[1] Hannover Med Sch, Dept Cardiothorac Transplantat & Vasc Surg, Hannover, Germany

[2] Univ Leipzig, Ctr Heart, Clin Heart Surg, D-04289 Leipzig, Germany

[3] Royal Perth Hosp, Adv Heart Failure & Cardiac Transplant Serv, Perth, WA 6001, Australia

[4] St Vincents Hosp, Heart Lung Transplant Unit, Sydney, NSW 2010, Australia

[5] Med Univ Vienna, Dept Cardiac Surg, Vienna, Austria

[6] Oslo Univ Hosp, Dept Cardiothorac Surg, Oslo, Norway

[7] Papworth Hosp NHS Fdn Trust, Dept Transplantat, Cambridge, England

[8] Harefield Hosp, Royal Brompton & Harefield NHS Trust, Dept Cardiothorac Transplantat & Mech Support, London, England

[9] HeartWare Inc, Framingham, MA USA

[10] Freeman Rd Hosp, Dept Cardiothorac Surg, Newcastle Upon Tyne, Tyne & Wear, England

关键词: HeartWare;    HVAD;    ventricular assist system;    ReVOLVE Registry;   

DOI  :  10.1016/j.healun.2014.01.856

来源: Elsevier

【 摘 要 】

BACKGROUND: The post-market Registry to Evaluate the HeartWare Left Ventricular Assist System (ReVOLVE) is an investigator-initiated registry established to collect post-CE Mark Trial clinical data on patients receiving a HeartWare ventricular assist device (HVAD) in the European Union and Australia. METHODS: The ReVOLVE is a multi-center, prospective, single-arm registry performed at seven centers in Europe and two in Australia. Herein we describe a total of 254 commercial HVAD implants according to labeled indications between February 2009 and November 2012. Summary statistics included patients' demographics, adverse events, length of support and outcomes. RESULTS: Compared with the clinical trial supporting the CE Mark of the HeartWare system, patient selection differed in that patients were older, and there were higher proportions of females and patients with idiopathic cardiomyopathies in the ReVOLVE cohort. Duration of support ranged from 1 to 1,057 days, with a mean of 363 +/- 280 days (median 299.5 days). Transplantation was done in 56 patients (22%), explant for recovery was performed in 3 patients (1%), 43 died while on support (17%), and 152 (60%) remain on the device. Success in patients with the HeartWare system was 87% at 6 months, 85% at 1 year, 79% at 2 years and 73% at 3 years. Adverse event rates, were low, comparable or improved when compared to the CE Mark Trial. CONCLUSION: Real-world use of the HeartWare system continues to demonstrate excellent clinical outcomes in patients supported with the device. (C) 2014 International Society for Heart and Lung Transplantation. All rights reserved.

【 授权许可】

Free